Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease

Aiko Fukui, Naoto Kawabe, Senju Hashimoto, Michihito Murao, Takuji Nakano, Hiroaki Shimazaki, Toshiki Kan, Kazunori Nakaoka, Masashi Ohki, Yuka Takagawa, Tomoki Takamura, Hiroyuki Kamei, Kentaro Yoshioka

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

AIM: To evaluate the efficacy of vitamin E treatment on liver stiffness in nonalcoholic fatty liver disease (NAFLD). METHODS: Thirty-eight NAFLD patients were administered vitamin E for > 1 year. The doses of vitamin E were 150, 300, or 600 mg; three times per day after each meal. Responses were assessed by liver enzyme levels [aspartate aminotransferase (AST), alanine aminotranferease (ALT), and γ-glutamyl transpeptidase (γ-GTP)], noninvasive scoring systems of hepatic fibrosis-4 [FIB-4 index and aspartate aminotransferase-to-platelet index (APRI)], and liver stiffness [velocity of shear wave (Vs)] measured by acoustic radiation force impulse elastography. Vs measurements were performed at baseline and 12 mo after baseline. The patients were genotyped for the patatin-like phospholipase domain containing 3 (PNPLA3 ) polymorphisms and then divided into either the CC/CG or GG group to examine each group's responses to vitamin E treatment. RESULTS: We found marked differences in the platelet count, serum albumin levels, alkaline phosphatase levels, FIB-4 index, APRI, and Vs at baseline depending on the PNPLA3 polymorphism. AST, ALT, and γ-GTP levels (all P < 0.001); FIB-4 index (P = 0.035); APRI (P < 0.001); and Vs (P < 0.001) significantly decreased from baseline to 12 mo in the analysis of all patients. In the subset analyses of PNPLA3 genotypes, AST levels (P = 0.011), ALT levels (P < 0.001), γ-GTP levels (P = 0.005), APRI (P = 0.036), and Vs (P = 0.029) in genotype GG patients significantly improved, and AST and ALT levels (both P < 0.001), γ-GTP levels (P = 0.003), FIB-4 index (P = 0.017), and APRI (P < 0.001) in genotype CC/CG patients. CONCLUSION: One year of vitamin E treatment improved noninvasive fibrosis scores and liver stiffness in NAFLD patients. The responses were similar between different PNPLA3 genotypes.

Original languageEnglish
Pages (from-to)2749-2756
Number of pages8
JournalWorld Journal of Hepatology
Volume7
Issue number27
DOIs
Publication statusPublished - 2015

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint

Dive into the research topics of 'Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this